New 'Living Drug' trial targets rare, debilitating blood disorder
NCT ID NCT07250269
Summary
This early-stage study is testing a new type of treatment called GC012F, a CAR-T cell therapy, for Chinese adults with AL amyloidosis that has come back or hasn't responded to prior treatments. The main goals are to find a safe and tolerable dose and to see if the therapy can help control the disease. It involves genetically modifying a patient's own immune cells to target and fight the abnormal plasma cells causing the illness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY AL AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
NOT_YET_RECRUITINGBeijing, 100034, China
-
Research Site
NOT_YET_RECRUITINGBeijing, 100070, China
-
Research Site
RECRUITINGBeijing, CN-100730, China
-
Research Site
RECRUITINGChangchun, 130021, China
-
Research Site
NOT_YET_RECRUITINGGuangzhou, 510100, China
-
Research Site
NOT_YET_RECRUITINGHangzhou, 310003, China
-
Research Site
RECRUITINGSuzhou, 215006, China
-
Research Site
RECRUITINGWenzhou, 325000, China
-
Research Site
NOT_YET_RECRUITINGWuhan, 430022, China
Conditions
Explore the condition pages connected to this study.